文献速递妇科

绝经激素治疗的成本效果分析

Cost-Effectiveness Analysis of Menopausal Hormone Therapy.
PubMed 文献 · Obstet Gynecol · 2026-08-13

该研究用马尔可夫模型评估50岁有血管舒缩症状女性使用5年绝经激素治疗(MHT)的成本效果。经皮雌二醇单用或无子宫者联用微粒化黄体酮,相比不用MHT均具绝对优势,节省费用并增加质量调整生命年(QALY),ASCVD风险降低是主要驱动因素。

要点

  • 50岁起始、用5年的MHT相比不用MHT具绝对成本效果优势。
  • 每万人终生,雌二醇单用节省$135,396,560并增加33,196 QALY。
  • ASCVD风险降低是模型成本效果的最大驱动因素。

核心结论

  • 模型提示对50岁起始、使用5年的典型绝经症状患者,MHT具有成本效果。
  • MHT降低ASCVD风险是成本效果的最大驱动因素。

研究设计与样本

  • 马尔可夫模型,假设50岁有血管舒缩症状女性,比较MHT与不用MHT,使用5年。
  • 无子宫者用经皮雌二醇单用,有子宫者用经皮雌二醇联合微粒化黄体酮。
  • 卫生系统视角,效果以QALY表示,支付意愿阈值设为每QALY $100,000。

主要发现

  • 每10,000例终生,雌二醇单用相比不用MHT节省$135,396,560,增加33,196 QALY。
  • 雌二醇单用组:ASCVD少259例、结肠癌少105例、乳腺癌多87例、髋部骨折少181例、死亡少647例。
  • 微粒化黄体酮组相比不用MHT节省$127,738,990,增加33,083 QALY。
  • 微粒化黄体酮组:ASCVD少285例、结肠癌多18例、乳腺癌多46例、髋部骨折少183例、死亡少615例。
  • 敏感性分析显示ASCVD相关变量对模型影响最大;概率敏感性分析在支付意愿阈值至$200,000时两种MHT策略均具绝对优势。

关键数值与推荐

  • 支付意愿阈值:每QALY $100,000。
  • 雌二醇单用组每10,000例终生:节省$135,396,560,增加33,196 QALY。
  • 微粒化黄体酮组每10,000例终生:节省$127,738,990,增加33,083 QALY。

临床怎么用

  • 对50岁有血管舒缩症状女性,可考虑起始5年MHT,因模型显示其具成本效果。
  • 无子宫者可选经皮雌二醇单用,有子宫者可选经皮雌二醇联合微粒化黄体酮。
  • 决策时应关注ASCVD风险降低对成本效果的主导作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cost effectiveness of menopausal hormone therapy (MHT) based on the risk-benefit profiles of current MHT formulations. METHODS: We used a Markov model to examine the cost effectiveness of MHT for hypothetical 50-year-old women with vasomotor symptoms compared with transdermal estradiol (E2) alone for patients without a uterus and transdermal E2 in combination with micronized progesterone for patients with a uterus, assuming 5 years of use. Using a health system perspective, we expressed the effectiveness in quality-adjusted life years (QALYs), and the willingness-to-pay threshold was set to $100,000 per QALY gained. We derived probabilities, cost data, and utilities from the literature and estimated the incremental cost-effectiveness ratios between the MHT and no MHT strategies as our primary outcome. Secondary outcomes included the number of cases of cardiovascular disease, breast cancer, colon cancer, and hip fracture and the number of deaths. RESULTS: Use of MHT demonstrated absolute dominance over not using MHT for both the E2 and E2+micronized progesterone arms. Per 10,000 patients over a lifetime, E2 compared with no MHT was $135,396,560 less expensive, resulted in a gain of 33,196 QALYs, and was associated with 259 fewer cases of atherosclerotic cardiovascular disease (ASCVD), 105 fewer colon cancer cases, 87 more breast cancer cases, 181 fewer hip fractures, and 647 fewer deaths. Micronized progesterone compared with no MHT was $127,738,990 less expensive, resulted in a gain of 33,083 QALYs, and was associated with 285 fewer cases of ASCVD, 18 more colon cancer cases, 46 more breast cancer cases, 183 fewer hip fractures, and 615 fewer deaths. Sensitivity analysis showed that variables related to ASCVD had the most effect on the model. Probabilistic sensitivity analysis revealed absolute dominance for both MHT strategies at all willingness-to-pay thresholds up to $200,000. CONCLUSION: Our model suggests that MHT is cost effective for typical patients experiencing menopausal symptoms with initiation of MHT at age 50 years and use for 5 years. The reduction in ASCVD risk by MHT is the largest driver of cost effectiveness in the model.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gill E, Zeng W, Shvartsman K, et al. Cost-Effectiveness Analysis of Menopausal Hormone Therapy. Obstet Gynecol. 2026. PMID: 42594384. doi:10.1097/AOG.0000000000006404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。